EUVIMEDEUVIMED entdecken
Open Access

Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer

Mackenzie W Sullivan, Stephen Graves, Anusha Adkoli, Qin Zhou, Alexia Iasonos, Lora H Ellenson, Dennis S Chi, Carol Aghajanian, Ying L Liu iD, Yukio Sonoda, Roisin E O'Cearbhaill, Britta Weigelt iD und 1 weitere

Cancer · 2025

DOI: 10.1002/cncr.35523 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Mackenzie W Sullivan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Homologous Recombination, Carcinoma, Ovarian Epithelial. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, Cycle for Survival.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Homologous recombination deficiency (HRD) testing is used to determine the appropriateness of poly ADP‐ribose polymerase inhibitors for patients with epithelial ovarian cancer and no germline/somatic BRCA1/2 alterations. Myriad MyChoice CDx reports a genomic instability score (GIS) to quantify the level of HRD, with a positive score defined as ≥42. The authors sought to define factors associated with obtaining an inconclusive HRD test result.

Methods

GIS was retrieved for patients at their institution with epithelial ovarian cancer without germline/somatic BRCA1/2 deleterious alterations who underwent HRD testing from April 2020–August 2023. Clinical data were abstracted from the medical record.

Results

Of 477 HRD test results identified, 57 (12%) were inconclusive. High‐grade serous ovarian cancers had higher GIS than other histologic types (median 29 vs. 21, p < .001). Most HRD cases were of high‐grade serous histology; no cases with clear cell or endometrioid histology were HRD‐positive. On univariate analysis, interval versus primary cytoreductive surgery, other specimen sources versus surgical specimens, and chemotherapy exposure were risk factors for inconclusive HRD testing. On multivariable analysis, chemotherapy exposure, and tissue source were associated with an inconclusive test result, with surgical specimens more likely to yield a conclusive result than other sources (biopsy, cytology, other). Age, stage, self‐reported race, and histology were not associated with an inconclusive result.

Conclusions

Surgical tissue was more likely to yield a conclusive HRD test result versus other sources of epithelial ovarian cancer tissue acquisition. When feasible, laparoscopic biopsy before initiation of neoadjuvant chemotherapy may increase the likelihood of obtaining interpretable HRD test results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsHomologous RecombinationCarcinoma, Ovarian EpithelialHumansFemaleMiddle AgedAgedAdultGenetic TestingGenomic InstabilityBRCA1 ProteinPoly(ADP-ribose) Polymerase InhibitorsBRCA2 Protein

Stichwörter der Autor:innen

PARP inhibitorhomologous recombination deficiency testingmaintenance therapyovarian cancer

Substanzen

BRCA1 ProteinPoly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA1 protein, humanBRCA2 protein, human

Autor:innen und Institutionen

  • Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Obstetrics and Gynecology, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York, USA.
  • Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Ying L Liu, Britta Weigelt, Rachel N Grisham

Förderung

  • NIH HHS
  • NCI NIH HHS
  • Cycle for Survival
  • Breast Cancer Research Foundation

Zitieren

APA

Sullivan, M. W., Graves, S., Adkoli, A., Zhou, Q., Iasonos, A., Ellenson, L. H., Chi, D. S., Aghajanian, C., Liu, Y. L., Sonoda, Y., O'Cearbhaill, R. E., Weigelt, B., & Grisham, R. N. (2025). Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer. Cancer. https://doi.org/10.1002/cncr.35523

Vancouver

Sullivan MW, Graves S, Adkoli A, Zhou Q, Iasonos A, Ellenson LH, et al. Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer. Cancer. 2025. doi:10.1002/cncr.35523

BibTeX
@article{Sullivan2025,
  author = {Sullivan, Mackenzie W and Graves, Stephen and Adkoli, Anusha and Zhou, Qin and Iasonos, Alexia and Ellenson, Lora H and Chi, Dennis S and Aghajanian, Carol and Liu, Ying L and Sonoda, Yukio and O'Cearbhaill, Roisin E and Weigelt, Britta and Grisham, Rachel N},
  title = {Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35523}
}
Kostenlos starten →